Angiogenesis as a target for the treatment of ovarian cancer.
Shaw, Danielle Clamp, Andrew R
Shaw, Danielle
Clamp, Andrew R
Citations
Altmetric:
Abstract
Angiogenesis has been validated as a target in ovarian cancer through four randomized trials that have reported improved progression-free survival (PFS) in patients with ovarian cancer whose conventional treatment was supplemented with concurrent and maintenance administration of the antivascular endothelial growth factor (VEGF) antibody, bevacizumab. These trials [the International Collaborative Ovarian Neoplasm Group trial (ICON7), the Gynecologic Oncology Group trial (GOG218), OCEANS and AURELIA] have shown that the tumour vasculature is a valid target throughout the lifetime of patients with ovarian cancer. This review seeks to address some of the remaining questions surrounding the optimal strategy for the use of bevacizumab in ovarian cancer.
Description
Date
2013-09
Publisher
Collections
Keywords
Type
Article
Citation
Angiogenesis as a target for the treatment of ovarian cancer. 2013, 25 (5):558-65 Curr Opin Oncol